Patents by Inventor Navnit Hargovindas Shah

Navnit Hargovindas Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11185588
    Abstract: The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 30, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20200330600
    Abstract: The present invention relates to a pharmaceutical composition comprising a solid dispersion of a drug. In the composition, the drug is in substantially amorphous form.
    Type: Application
    Filed: November 25, 2019
    Publication date: October 22, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Antonio ALBANO, Dipen DESAI, James DiNUNZIO, Zenaida GO, Raman Mahadevan IYER, Harpreet K. SANDHU, Navnit Hargovindas SHAH
  • Publication number: 20190117775
    Abstract: The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20180369388
    Abstract: The present invention relates to a pharmaceutical composition comprising a solid dispersion of a drug. In the composition, the drug is in substantially amorphous form.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 27, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Antonio ALBANO, Dipen DESAI, James DiNUNZIO, Zenaida GO, Raman Mahadevan IYER, Harpreet K. SANDHU, Navnit Hargovindas SHAH
  • Patent number: 10034854
    Abstract: The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: July 31, 2018
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Steve Lomuscio, Hua Ma, Michael Allen Matchett, Harpreet K. Sandhu, Navnit Hargovindas Shah, Yu-E Zhang
  • Publication number: 20180153998
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 7, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20170266286
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: April 5, 2017
    Publication date: September 21, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Patent number: 9642911
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: May 9, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20170000764
    Abstract: The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.
    Type: Application
    Filed: July 1, 2016
    Publication date: January 5, 2017
    Inventors: Steve Lomuscio, Hua Ma, Michael Allen Matchett, Harpreet K. Sandhu, Navnit Hargovindas Shah, Yu-E Zhang
  • Patent number: 9427427
    Abstract: The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: August 30, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Steve Lomuscio, Hua Ma, Michael Allen Matchett, Harpreet K. Sandhu, Navnit Hargovindas Shah, Yu-E Zhang
  • Patent number: 9370492
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone, and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: June 21, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Hashim Ahmed, Lewis Bender, Martin Howard Infeld, Shingai Majuru, Wantanee Phuapradit, Navnit Hargovindas Shah, Zhongshui Yu
  • Publication number: 20150209294
    Abstract: There is provided a formulation comprising N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2(diethylamino)ethyl ester and poloxamer 188 which is manufactured by a hot melt process.
    Type: Application
    Filed: October 31, 2014
    Publication date: July 30, 2015
    Inventors: Ashish Chatterji, Harpreet K. Sandhu, Navnit Hargovindas Shah
  • Publication number: 20150057296
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20150044287
    Abstract: There is provided a film coated pharmaceutical composition comprising 5?-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400?), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Pharmaburst C or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet. This tablet disintegrates in water at 37° C. in a USP Disintegration Apparatus in less than 2 minutes, preferably 1 minute and have a hardness of 8-13 strong Cobb-Units.
    Type: Application
    Filed: October 22, 2014
    Publication date: February 12, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Mohammad Rashed, Navnit Hargovindas Shah
  • Patent number: 8889109
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: November 18, 2014
    Assignee: Hoffman-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Patent number: 8852634
    Abstract: The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I wherein the definitions are described in claim 1, or pharmaceutically acceptable acid addition salts thereof and a water soluble poloxamer in which the compound of formula I and the water soluble poloxamer are processed by hot melt extrusion, and then the hot melt extrudate is mixed with other ingredients to form a tablet, that is optionally coated with a composition comprising an immediate release film coating system and purified water. The invention also relates to such pharmaceutical compositions and hot melt extrudates.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: October 7, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hashim A. Ahmed, Susanne Page, Navnit Hargovindas Shah
  • Publication number: 20140206742
    Abstract: The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 24, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Steve Lomuscio, Hua Ma, Michael Allen Matchett, Harpreet K. Sandhu, Navnit Hargovindas Shah, Yu-E Zhang
  • Publication number: 20130331314
    Abstract: The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 12, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andreas Leiminer, Kai Lindenstruth, Dave Alan Miller, Emmanuel Scheubel, Navnit Hargovindas Shah
  • Patent number: 8222230
    Abstract: The present invention provides novel formulations of isobutyric acid (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-fluoro-2-isobutyryloxymethyl-4-methyl-tetrahydro-furan-3-yl ester) and hydroxypropylcellulose that provide high bulk density, low particle size better suited for improved compression and flow, good compression, and fast dissolution profiles.
    Type: Grant
    Filed: January 18, 2010
    Date of Patent: July 17, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ashish Chatterji, Dipen Desai, Harpreet Sandhu, Navnit Hargovindas Shah
  • Publication number: 20120129898
    Abstract: The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions.
    Type: Application
    Filed: January 4, 2012
    Publication date: May 24, 2012
    Inventors: Ashish Chatterji, Zedong Dong, Harpreet K. Sandhu, Navnit Hargovindas Shah